Ats vs ets guidelines for mx of cap
Reading File
Finding Sources
Searching PubMed
"community-acquired pneumonia" AND guideline
Searching the Web
ATS IDSA 2019 community acquired pneumonia guideline ERS ESCMID 2023 European guideline comparison management
Reading Web Page
https://www.idsociety.org/practice-guideline/community-acqui…
Finding Sources
Searching PubMed
"community-acquired pneumonia" AND guideline
Searching PubMed
"severe community-acquired pneumonia" AND ERS
Searching the Web
2025 ATS IDSA community acquired pneumonia guideline recommendations corticosteroids antibiotics duration official
Finding Sources
Reading Web Page
https://site.thoracic.org/press-releases/treatment-with-anti…
Assuming “ETS” means ERS/ESICM/ESCMID/ALAT. These are not directly equivalent guidelines:
- ATS/IDSA 2019, with a focused ATS 2025 update, addresses adult CAP across outpatient, ward, and ICU settings.
- ERS/ESICM/ESCMID/ALAT 2023 specifically addresses severe CAP (sCAP), usually ICU-level illness.
High-yield comparison for management of adult CAP
| Issue | ATS/IDSA 2019 plus ATS 2025 update | ERS/ESICM/ESCMID/ALAT 2023 sCAP |
|---|---|---|
| Scope | Full adult CAP pathway: diagnosis, admission, microbiology, empiric therapy, duration, follow-up | ICU/severe CAP: diagnostics, antibiotics, organ support, biomarkers, adjuncts |
| Site of care | Prefer PSI over CURB-65 to decide hospitalization, plus clinical judgment. Use ATS/IDSA major/minor criteria for severe CAP | Applies once sCAP is identified, generally with ICU assessment/support |
| Outpatient, no comorbidity | Amoxicillin 1 g PO q8h, doxycycline 100 mg q12h, or macrolide only if local pneumococcal macrolide resistance <25% | Not covered |
| Outpatient with comorbidity | Amox-clavulanate or cephalosporin plus azithromycin/clarithromycin or doxycycline; or respiratory fluoroquinolone monotherapy | Not covered |
| Non-severe inpatient | Beta-lactam plus macrolide, or respiratory fluoroquinolone monotherapy | Not primary focus |
| Severe inpatient/ICU | Beta-lactam plus macrolide preferred, or beta-lactam plus respiratory fluoroquinolone. Do not use fluoroquinolone monotherapy in severe CAP | Favors a beta-lactam plus macrolide strategy for sCAP; tends to prefer macrolide-containing combination therapy over beta-lactam plus fluoroquinolone |
| MRSA/Pseudomonas coverage | Add only with validated risk factors, especially prior respiratory isolation or recent hospitalization with IV antibiotics, and obtain cultures | Same stewardship principle: tailor to local ecology and individual multidrug-resistant pathogen risk |
| Microbiology | Blood/sputum cultures for severe CAP or if covering MRSA/Pseudomonas. Do not routinely test every non-severe inpatient | More diagnostic emphasis in sCAP, including obtaining microbiology early to enable de-escalation |
| Procalcitonin | Do not withhold initial antibiotics in radiographically confirmed CAP based on low procalcitonin | Can support shortening/discontinuing antibiotics with clinical improvement, but should not delay initial treatment of sCAP |
| Antibiotic duration | 2019: treat until clinically stable and for at least 5 days. The 2025 ATS update allows a minimum 3-day course for patients who achieve stability, with individualization | Shorter therapy guided by clinical response and, where used, procalcitonin-guided discontinuation; longer courses if complications or resistant pathogens |
| Corticosteroids | 2019: avoid routinely, except refractory septic shock. 2025 ATS: do not give for non-severe inpatient CAP; suggests systemic corticosteroids for severe CAP | Supports corticosteroids in appropriately selected sCAP, particularly where shock/inflammatory severe disease is present; avoid a blanket approach and assess viral influenza and contraindications |
| Respiratory virus positive | 2025 ATS: in an otherwise healthy outpatient with imaging-confirmed CAP and a positive respiratory viral test, empiric antibacterial therapy may be withheld. This is conditional, low-certainty evidence | Not the central question, because sCAP has substantial bacterial co-infection risk and generally receives prompt empiric antibiotics |
| Lung ultrasound | 2025 ATS: acceptable alternative to chest x-ray where operator expertise exists | Can be used as part of the diagnostic approach in critically ill sCAP |
Practical treatment framework
1. Non-severe CAP
Outpatient, healthy adult
- Amoxicillin or doxycycline.
- Use a macrolide alone only if local pneumococcal resistance is low.
Outpatient with comorbidities
- Amox-clav plus azithromycin or doxycycline, or
- Respiratory fluoroquinolone monotherapy.
Inpatient, non-severe
- Ceftriaxone or ampicillin-sulbactam plus azithromycin, or
- Respiratory fluoroquinolone monotherapy.
2. Severe CAP / ICU
Use:
- Anti-pneumococcal beta-lactam plus macrolide, for example ceftriaxone plus azithromycin.
Then add:
- MRSA therapy: vancomycin or linezolid, only if risk factors.
- Antipseudomonal beta-lactam: piperacillin-tazobactam, cefepime, meropenem, etc., only if risk factors.
The principal ERS distinction is a stronger emphasis on beta-lactam plus macrolide in sCAP rather than relying on beta-lactam plus fluoroquinolone.
Steroids: key exam difference
- ATS/IDSA 2019: no routine steroids in CAP, except treatment of refractory septic shock.
- ERS 2023 sCAP: supports selected corticosteroid use in severe disease.
- ATS 2025 moved closer to ERS for severe disease: suggest systemic steroids in severe CAP, but recommend against them in non-severe hospitalized CAP. The ATS 2025 summary makes this distinction explicit.
Take-home difference
ATS/IDSA gives the complete CAP algorithm and is more conservative about broad testing, anti-MRSA/antipseudomonal therapy, and steroids.
ERS/ESICM/ESCMID/ALAT is an ICU-focused severe-CAP guideline: it favors early combination therapy, structured microbiological work-up and de-escalation, organ support, and selected adjunctive steroids.
The 2019 ATS/IDSA guideline remains the core broad CAP reference, while the ERS severe-CAP guideline is specifically for sCAP.
Recent evidence may affect steroid practice: a 2025 systematic review of corticosteroids in hospitalized nonviral CAP reported updated results, but guideline application still depends on severity and patient selection (PMID: 40323455).
This is a shared conversation. Sign in to Orris to start your own chat.